6-氯-2-(呋喃-2-基)嘧啶-4-胺 | 856173-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-氯-2-(呋喃-2-基)嘧啶-4-胺
• 英文名称: 6-chloro-2-(2-furyl)pyrimidin-4-ylamine
• 英文别名: 6-chloro-2-(2-furyl)pyramidin-4-amine；6-chloro-2-(2-furyl)pyrimidin-4-amine；6-Chloro-2-(furan-2-yl)pyrimidin-4-amine
• CAS: 856173-22-3
• 化学式: C₈H₆ClN₃O
• 分子量: 195.608
• InChiKey: AVTXQVZJEJMHSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  6-氯-2-(呋喃-2-基)嘧啶-4-胺 在 肼 作用下， 以 乙醇 为溶剂， 反应 22.0h， 生成 2-(Furan-2-yl)-6-hydrazinylpyrimidin-4-amine
  参考文献：
  名称：

  2-Amino-N-pyrimidin-4-ylacetamides as A_2A Receptor Antagonists: 1. Structure−Activity Relationships and Optimization of Heterocyclic Substituents

  摘要：

  Previously we have described a novel series of potent and selective A(2A) receptor antagonists (e.g., 1) with excellent aqueous solubility.(1) While these compounds are efficacious A(2A) antagonists in vivo, the presence of an unsubstituted furyl moiety was a cause of some concern. In order to avoid the potential metabolic liabilities that could arise from an unsubstituted fury] moiety, an optimization effort was undertaken with the aim of replacing the unsubstituted furan with a more metabolically stable group while maintaining potency and selectivity. Herein, we describe the synthesis and SAR of a range of novel heterocyclic systems and the successful identification of a replacement for the unsubstituted furan moiety with a methylfuran or thiazole moiety while maintaining potency and selectivity.

  DOI：

  10.1021/jm701185v
• 作为产物：
  描述：

  4,6-dichloro-2-(furan-2-yl)pyrimidine 在 氨 作用下， 以 甲醇 、 水 为溶剂， 反应 20.0h， 以76%的产率得到6-氯-2-(呋喃-2-基)嘧啶-4-胺
  参考文献：
  名称：

  [EN] 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
  [FR] 2, 6-BISHETEROARYL-4-AMINOPYRIMIDINES UTILISEES EN TANT QU'ANTAGONISTES DES RECEPTEURS DE L'ADENOSINE

  摘要：

  公式（I）的4-氨基嘧啶衍生物，包括其药学上可接受的盐，其中R1和R2是阿多诺苷A2A受体拮抗剂，可用于治疗帕金森病等运动障碍。

  公开号：

  WO2005058883A1

文献信息

• 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists
  申请人：Crespo Crespo Maria Isabel

  公开号：US20080058356A1

  公开（公告）日：2008-03-06

  4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are adenosine A 2A receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.

  公式（I）的4-氨基嘧啶衍生物，其中包括杂环基团，以及其药学上可接受的盐，其中R1和R2是阿多诺西嗪A2受体拮抗剂，适用于治疗运动障碍，如帕金森病。
• Substituted Pyrimidines as Adenosine Receptor Antagonists
  申请人：Slee Deborah

  公开号：US20080275064A1

  公开（公告）日：2008-11-06

  Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.

  式(I)的化合物，包括药学上可接受的盐、酯、溶剂合物和立体异构体，其中R1、R2和R3的定义如本文所述。含有式(I)化合物的制药组合物，以及与其使用作为腺苷受体拮抗剂相关的方法，特别是A2A腺苷受体亚型的拮抗剂。
• SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Lanier Marion

  公开号：US20100234341A1

  公开（公告）日：2010-09-16

  Compounds of formula (I) including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  公式（I）的化合物，包括药学上可接受的盐、酯、溶剂和立体异构体，其中R1、R2和R3的定义如本文所述。本发明还公开了含有结构（I）化合物的制药组合物，以及与其使用相关的方法。
• Identification of Novel, Water-Soluble, 2-Amino-<i>N</i>-pyrimidin-4-yl Acetamides as A_2A Receptor Antagonists with In Vivo Efficacy
  作者：Deborah H. Slee、Xiaohu Zhang、Manisha Moorjani、Emily Lin、Marion C. Lanier、Yongsheng Chen、Jaimie K. Rueter、Sandra M. Lechner、Stacy Markison、Siobhan Malany、Tanya Joswig、Mark Santos、Raymond S. Gross、John P. Williams、Julio C. Castro-Palomino、María I. Crespo、Maria Prat、Silvia Gual、José-Luis Díaz、Jenny Wen、Zhihong O’Brien、John Saunders

  DOI：10.1021/jm070623o

  日期：2008.2.1

  Potent adenosine hA(2A) receptor antagonists are often accompanied by poor aqueous solubility, which presents issues for drug development. Herein we describe the early exploration of the structure-activity relationships of a lead pyrimidin-4-yl acetamide series to provide potent and selective 2-amino-N-pyrimidin4-yl acetamides as hA(2A) receptor antagonists with excellent aqueous solubility. In addition, this series of compounds has demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's disease, despite having reduced potency for the rat A(2A) receptor versus the human A2A receptor.
• WO2008/70661
  申请人：——

  公开号：——

  公开（公告）日：——